drugset / Trial / NCT04634513
Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122
RandomizedSequentialQuadruple-blindPrevention
Summary
The purpose of this study is to determine whether a live, oral, combined Shigella-ETEC vaccine candidate, known as strain CVD 1208S-122, is safe and immunogenic.
Timeline
- Start
- 2022-09-29
- Primary completion
- 2024-10-01
- Completion
- 2024-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVD 1208S-122 | Vaccine | 1e+08 unknown | Oral |
| Subject | CVD 1208S-122 | Vaccine | 1e+09 unknown | Oral |
| Subject | CVD 1208S-122 | Vaccine | 1e+10 unknown | Oral |